A randomized prospective open-label controlled trial comparing the performance of a connected monitoring interface versus physical routine monitoring in patients …

…, N Filippi, S Marouen, H Letaief, P Le Blay… - …, 2021 - academic.oup.com
Objectives In RA, telemedicine may allow tight control of disease activity while reducing hospital
visits. We developed a smartphone application connected with a physician’s interface to …

Handgrip strength measured by a dynamometer connected to a smartphone: a new applied health technology solution for the self-assessment of rheumatoid arthritis …

F Espinoza, P Le Blay, D Coulon, S Lieu… - …, 2016 - academic.oup.com
Objective. The aim was to analyse the accuracy of a hand dynamometer connected to a
smartphone to assess RA disease activity through the measurement of handgrip strength (HGS). …

[PDF][PDF] Risk of malignancy including non-melanoma skin cancers with anti-tumour necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of …

P Le Blay, G Mouterde, T Barnetche… - Clinical and …, 2012 - clinexprheumatol.org
Objective To assess the risk of malignancy in patients with rheumatoid arthritis (RA)
receiving tumour necrosis factor (TNF) antagonists through a meta-analysis of data from …

Musculoskeletal symptoms in patients with cryopyrin‐associated periodic syndromes: a large database study

…, A Duquesne, P Le Blay, C Le Jeunne… - Arthritis & …, 2015 - Wiley Online Library
Objective To determine the type and frequency of musculoskeletal symptoms at onset and
during followup of cryopyrin‐associated periodic syndromes (CAPS). Methods We …

Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized …

P Le Blay, G Mouterde, T Barnetche, J Morel… - The Journal of …, 2012 - jrheum.org
Objective. To assess the risk of total malignancy and nonmelanoma skin cancers (NMSC) in
patients with rheumatoid arthritis (RA) receiving certolizumab and golimumab through a …

Real‐world experience and impact of canakinumab in cryopyrin‐associated periodic syndrome: results from a French observational study

…, O Fain, G Grateau, P Pillet, P Le Blay… - Arthritis care & …, 2017 - Wiley Online Library
Objective The ENVOL study was designed to assess the psychosocial impact of disease and
therapy in a French cohort of cryopyrin‐associated periodic syndromes (CAPS) patients (…

A severe Whipple disease with an immune reconstitution inflammatory syndrome: an additional case of thalidomide efficiency

P Le Blay, H Rakotonirainy, JC Lagier, D Raoult… - Joint Bone Spine, 2014 - Elsevier
We report the case of a 38-year-old man who presented with severe diarrhea, weight loss of
10 kg, ankles paresthesia and severe motor weakness in the left fibular nerve territory after …

Biologic disease-modifying antirheumatic drug (bDMARD)-induced neutropenia: a registry from a retrospective cohort of patients with rheumatic diseases treated with …

F Espinoza, P Le Blay, B Combe - The Journal of rheumatology, 2017 - jrheum.org
Objective. To examine the rate, risks factors, and consequences of neutropenia induced by
intravenous (IV) biologic disease-modifying antirheumatic drugs (bDMARD). Methods. We …

Association of TRAF1-C5 with risk of uveitis in juvenile idiopathic arthritis

YM Pers, P Le Blay, C Ludwig, C Rittore, G Tejedor… - Joint Bone Spine, 2017 - Elsevier
… Author links open overlay panel Yves-Marie Pers a b 1 , Pierre Le Blay a b 1 , Catherine
Ludwig c , … Pierre Le Blay participated in the design of the study, collected data from the medical …

[HTML][HTML] Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study

C Ladhari, P Le Blay, T Vincent, A Larbi… - BMC rheumatology, 2020 - Springer
Background Strategic drug therapy for rheumatoid arthritis (RA) patients with prolonged
remission is not well defined. According to recent guidelines, tapering biological Disease-…